Finally, bortezomib, a proteasome inhibitor used for treating relapsed MCL, effectively induced apoptosis among MCL cells while reducing the expression of Bmi1 and increasing miR-16 levels. This evidence concerns the gene BMI1 and mantle cell lymphoma.